Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity


Autoria(s): Cohen, Ricardo V.; Pinheiro, Jose C.; Schiavon, Carlos A.; Salles, Joao E.; Wajchenberg, Bernardo L.; Cummings, David E.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

24/10/2013

24/10/2013

2012

Resumo

OBJECTIVE-Roux-en-Y gastric bypass (RYGB) ameliorates type 2 diabetes in severely obese patients through mechanisms beyond just weight loss, and it may benefit less obese diabetic patients. We determined the long-term impact of RYGB on patients with diabetes and only class 1 obesity. RESEARCH DESIGN AND METHODS-Sixty-six consecutively selected diabetic patients with BMI 30-35 kg/m(2) underwent RYGB in a tertiary-care hospital and were prospectively studied for up to 6 years (median 5 years [range 1-6]), with 100% follow-up. Main outcome measures were safety and the percentage of patients experiencing diabetes remission (HbA(1c) <6.5% without diabetes medication). RESULTS-Participants had severe, longstanding diabetes, with disease duration 12.5 +/- 7.4 years and HbA(1c) 9.7 +/- 1.5%, despite insulin and/or oral diabetes medication usage in everyone. For up to 6 years following RYGB, durable diabetes remission occurred in 88% of cases, with glycemic improvement in 11%. Mean HbA(1c) fell from 9.7 +/- 1.5 to 5.9 +/- 0.1% (P < 0.001), despite diabetes medication cessation in the majority. Weight loss failed to correlate with several measures of improved glucose homeostasis, consistent with weight-independent antidiabetes mechanisms of RYGB. C-peptide responses to glucose increased substantially, suggesting improved beta-cell function. There was no mortality, major surgical morbidity, or excessive weight loss. Hypertension and dyslipidemia also improved, yielding 50-84% reductions in predicted 10-year cardiovascular disease risks of fatal and nonfatal coronary heart disease and stroke. CONCLUSIONS-This is the largest, longest-term study examining RYGB for diabetic patients without severe obesity. RYGB safely and effectively ameliorated diabetes and associated comorbidities, reducing cardiovascular risk, in patients with a BMI of only 30-35 kg/m(2).

Municipal Health Authority, Marcia Maria Braido Hospital, Sao Paulo, Brazil

Municipal Health Authority, Marcia Maria Braido Hospital, Sao Paulo, Brazil [22/02]

Covidien

Covidien

Ethicon EndoSurgery

Ethicon Endo-Surgery

Identificador

DIABETES CARE, ALEXANDRIA, v. 35, n. 7, supl. 1, Part 1, pp. 1420-1428, JUL, 2012

0149-5992

http://www.producao.usp.br/handle/BDPI/35862

10.2337/dc11-2289

http://dx.doi.org/10.2337/dc11-2289

Idioma(s)

eng

Publicador

AMER DIABETES ASSOC

ALEXANDRIA

Relação

DIABETES CARE

Direitos

closedAccess

Copyright AMER DIABETES ASSOC

Palavras-Chave #BODY-MASS INDEX #BARIATRIC SURGERY #GASTROINTESTINAL SURGERY #LESS-THAN-35 KG/M(2) #METABOLIC SURGERY #WEIGHT-LOSS #LIFE-STYLE #MELLITUS #METAANALYSIS #BMI #ENDOCRINOLOGY & METABOLISM
Tipo

article

original article

publishedVersion